The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population‐based case–control study
Australasian Journal of Dermatology · 2024
DOI: 10.1111/ajd.14359 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von Anna Lyakhovitsky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Sheba Medical Center, Ramat-Gan, Israel. Hauptthemen laut MEDLINE: Finasteride, Alopecia, Prostatic Hyperplasia, Mental Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
There is a long‐standing debate if finasteride, a medication used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA), can cause psychiatric side effects.
Objective
The goal of this large‐scale population‐based study was to determine whether finasteride therapy for BPH and AGA is associated with the emergence of mental health conditions.
Methods
This observational case–control study compared the data from patients with BPH who received finasteride 5 mg daily and patients with AGA who received finasteride 1 mg daily with age‐ and gender‐matched controls. The incidence of psychological health outcomes such as depression, anxiety, neuroses, bipolar disorder, schizophrenia, psychoses and alcohol abuse within 2 years of the initiation of finasteride therapy has been evaluated and compared between the finasteride groups and controls.
Results
The BPH group included 307 men with a mean age of 61.5 (±17.4) years and 1218 controls. Mental health outcomes recorded in 2.3% of the patients, with no significant increase in rate when compared to controls. The AGA group consisted of 23,227 men with a mean age of 31.4 (±10.3) years and 39,444 controls. One percent of AGA patients developed psychiatric disorders. In comparison to controls, patients with AGA had higher rates of anxiety and depression (0.6% vs. 0.4%, p = 0.04, and 0.5% vs. 0.4%, p = 0.007, respectively). In multivariate regression models, finasteride was found as one of the risk factors for anxiety (OR 1.449, p = 0.002) and depression (OR 1.439, p = 0.003) when stratified to age, sector, socioeconomic status and comorbidities.
Conclusions
According to our research, finasteride users had a very low rate of adverse mental health effects, with no increase in psychological sequelae in BPH patients and a slight increase in anxiety and depression in AGA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Sheba Medical Center, Ramat-Gan, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Dermatology, Meir Medical Center, Kfar Saba, Israel.
- Clalit Health Services, Tel Aviv, Israel.
- Siaal Research Center for Family Medicine and Primary Care, Beer Sheva, Israel.
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
ORCID-Profile: Eran Galili, Khalaf Kridin
Zitieren
APA
Lyakhovitsky, A., Amichai, B., Galili, E., Cohen, A., Kridin, K., Segal, Z., & Netzer, D. (2024). The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population‐based case–control study. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14359
Vancouver
Lyakhovitsky A, Amichai B, Galili E, Cohen A, Kridin K, Segal Z, et al. The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population‐based case–control study. Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14359
BibTeX
@article{Lyakhovitsky2024,
author = {Lyakhovitsky, Anna and Amichai, Boaz and Galili, Eran and Cohen, Arnon and Kridin, Khalaf and Segal, Zvi and Netzer, Doron},
title = {The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population‐based case–control study},
journal = {Australasian Journal of Dermatology},
year = {2024},
doi = {10.1111/ajd.14359}
}
EUVIMED